Optimize your pharmaceutical portfolio strategy

Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Pharma 360

Global Oncology Opportunities & Trends 2025: Key Markets, Indications and Product

13 May 2022

Join Informa Pharma Intelligence for the “Global Oncology Opportunities” webinar!

In Vivo

Outlook 2022: What Next for Pharma After a Year of Innovation and Growth?

02 Mar 2022

Look ahead with our Pharma Outlook 2022 Extract as we discuss what's coming up in the biopharma space.

In Vivo

Five (Non-COVID) Clinical Trial Hits Of 2021

By Alex Shimmings 05 Jan 2022

2021 may have been dominated by the continuing coronavirus pandemic, but that did not stop industry’s more bread and butter R&D activities. Here, In Vivo takes a look at five of the more notable clinical trial hits of the year.

In Vivo

Innovation Trends Point To More Positives For Health Care Investors

By Ashley Yeo 28 Dec 2021

At the end of a turbulent year for health care, COVID-19 is still dominating the thoughts of stakeholders, but CMS patent attorneys Jane Hollywood and Rob Stephen are encouraged by the innovation and investment trends that are making it an exciting time to be in the thick of the action.

In Vivo

How Will Pfizer Leverage External Innovation After BioNTech Jackpot?

By Lucie Ellis-Taitt 22 Nov 2021

Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.

In Vivo

A New Generation Invents Pharma’s Mirrored Future

By Joanne Shorthouse 17 Nov 2021

Young businesses are getting set to disrupt every inch of the healthcare space with digital twin technology. Outlook spoke to two startups on the brink of a data dawn.

In Vivo

Optimism About Alzheimer’s Disease: Gene Therapy, Digital Therapeutics And New Biomarkers

By Ben Comer 14 Oct 2021

Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.

In Vivo

In Vivo Outlook 2021 Report

08 Oct 2021

The highly anticipated Outlook 2022 report from Informa Pharma Intelligence is coming soon. Reach the thousands of senior decision makers who eagerly await this pharma industry ranking and review for the year ahead, with sponsorship opportunities that align your brand with our trusted information.

Biomedtracker, Datamonitor Healthcare

Key Potential Drug Launches in 2022

23 Sep 2021

Released July 22, 2021. Contains information like likelihood of approval (LOA) ratings and upcoming catalysts that are current as of April 2021.

Biomedtracker, Datamonitor Healthcare

2020 Deal-Making Roundup

21 Sep 2021

Against a backdrop of unprecedented disruption, the biopharma and medtech industries reached incredible heights for deal-making activity during 2020.

In Vivo

How Should Opioid Settlement Dollars Be Spent? It’s Complicated

By Ben Comer 07 Sep 2021

Treating opioid addiction successfully requires an individualized approach, and a lot of money. Executives at addiction treatment centers discuss existing barriers in the recovery pathway and the need to destigmatize addiction and mental health disorders.

In Vivo

Critical Insights into Market Access

18 Aug 2021

Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

In Vivo

‘We Have A Lot Of Work To Do,’ Says Head Of HIV + Hepatitis Policy Institute

By William Masters 16 Aug 2021

Progress in reducing HIV infections has plateaued in the US. But with bipartisan support, federal funding and momentum in drug development there is reason for optimism, says HIV + Hepatitis Policy Institute executive director Carl Schmid.

In Vivo

Biotechs Choosing Brazil For Drug Development And Early Sales

By Mark Ratner 12 Aug 2021

Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.

Datamonitor Healthcare, Biomedtracker, Scrip

2021 Post-ASCO Insights and Analysis

11 Aug 2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.